Freestone Grove Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Freestone Grove Partners’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.9M	Buy	+881,688	New	+$13.5M	0.12%	210

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Freestone Grove Partners's ADPT Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 881,688 shares worth $18.9M. The stake represents 0.12% of the portfolio and ranks #210 among its holdings.

300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Freestone Grove Partners held 881,688 shares of Adaptive Biotechnologies worth $18.9M as of Q2 2026.
Adaptive Biotechnologies was a new Freestone Grove Partners position in Q2 2026.
Adaptive Biotechnologies made up 0.12% of Freestone Grove Partners's portfolio in Q2 2026, its #210 holding.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.